What is it about?
We hypothesized that genetic polymorphisms in methylenetetrahydrofolate reductase (MTHFR) gene are associated with prostate cancer risk.
Featured Image
Photo by Timothy Dykes on Unsplash
Why is it important?
It is well known that hereditary factors contribute to prostate cancer susceptibility. During the last decade genetic polymorphism of methylenetetrahydrofolate reductase (MTHFR) has gotten an increased attention as a potential genetic marker associated with the cancer risk. The human 5,10-MTHFR gene is located at the end of the short arm of chromosome 1 (1p36.3), and the total length of the gene cDNA is 2.2 kb. This locus has been associated with disease risk in family studies We have no disclosures to report. We have no conflict of interest whether of a financial or other nature. We did not make any financial arrangement with a company.We have no commercial affiliations to report.
Perspectives
The MTHFR C677T, A1298C, and G1793A polymorphismsmay be functionally relevant as evidenced by their associations with the risk of developing prostate cancer. These data, once replicated by other studies, could facilitate identify at risk populations for cancer prevention. Because our findings suggest that folate metabolism is important in the etiology of prostate cancer, further investigation of gene–gene and gene–environment interaction in folate metabolism is necessary.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: A case-control study, The Prostate, June 2010, Wiley,
DOI: 10.1002/pros.21200.
You can read the full text:
Resources
Contributors
The following have contributed to this page
